SCHEMBL3607847

SCHEMBL3607847

CSc1ccc(N2CC3CN(C(=O)OC(C)(C)C)CCN3C2=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.54
USP30 Q70CQ3 2/20 0.52
SCN9A Q15858 1/20 0.47
LIPE Q05469 2/20 0.40
FPR2 P25090 2/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38
TP53 P04637 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
MMP1 P03956 1/20 0.36
MMP3 P08254 1/20 0.36
MMP7 P09237 1/20 0.36
MMP9 P14780 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22390396 0.88 USP30 (0.52) GPR119USP30SCN9ALIPEFPR2
SCHEMBL22390394 0.88 USP30 (0.52) GPR119USP30SCN9ALIPEFPR2
SCHEMBL3607760 0.88 USP30 (0.61) GPR119USP30SCN9AFPR2LMNA
SCHEMBL20616391 0.87 USP30 (0.52) GPR119USP30SCN9ALIPEFPR2
SCHEMBL3609803 0.87 USP30 (0.52) USP30SCN9ALIPEALDH1A1LMNA
SCHEMBL23897991 0.87 USP30 (0.52) GPR119USP30SCN9ALIPEFPR2
SCHEMBL31524262 0.87 USP30 (0.52) GPR119USP30SCN9ALIPEFPR2
SCHEMBL3604813 0.86 USP30 (0.59) GPR119USP30SCN9AFPR2SMARCA2
SCHEMBL22390314 0.86 GPR119 (0.53) GPR119USP30SCN9ALIPEFPR2
SCHEMBL22390313 0.86 GPR119 (0.53) GPR119USP30SCN9ALIPEFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2039695-A1 BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof HTR2C, HTR5A, HTR2A GPR119 268/4885USP30 4815/4885SCN9A 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.